Canada markets open in 20 minutes
  • S&P/TSX

    19,991.88
    +105.94 (+0.53%)
     
  • S&P 500

    4,207.27
    -2.97 (-0.07%)
     
  • DOW

    33,336.67
    +27.16 (+0.08%)
     
  • CAD/USD

    0.7823
    -0.0014 (-0.17%)
     
  • CRUDE OIL

    92.91
    -1.43 (-1.52%)
     
  • BTC-CAD

    30,461.61
    -1,413.24 (-4.43%)
     
  • CMC Crypto 200

    566.37
    -8.38 (-1.46%)
     
  • GOLD FUTURES

    1,810.30
    +3.10 (+0.17%)
     
  • RUSSELL 2000

    1,975.26
    +6.01 (+0.31%)
     
  • 10-Yr Bond

    2.8620
    -0.0260 (-0.90%)
     
  • NASDAQ futures

    13,393.75
    +82.50 (+0.62%)
     
  • VOLATILITY

    19.93
    +0.19 (+0.96%)
     
  • FTSE

    7,493.09
    +27.18 (+0.36%)
     
  • NIKKEI 225

    28,546.98
    +727.65 (+2.62%)
     
  • CAD/EUR

    0.7613
    +0.0025 (+0.33%)
     

HLS Therapeutics to Present at Stifel GMP's Future of Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

TORONTO, Dec. 1, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, Chief Executive Officer, and Tim Hendrickson, Chief Financial Officer, will present at Stifel GMP's 2nd Annual Future of Healthcare Conference on Wednesday December 8, 2021 at 10:30 a.m. Eastern Standard Time. The conference will be held in a virtual meeting format.

An audio webcast of the Company's presentation will be available at: https://wsw.com/webcast/stifel62/register.aspx?conf=stifel62&page=hls.to&url=https://wsw.com/webcast/stifel62/hls.to/2364360

ABOUT HLS THERAPEUTICS INC.
Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information, please visit: www.hlstherapeutics.com

SOURCE HLS Therapeutics Inc.

Cision
Cision

View original content: http://www.newswire.ca/en/releases/archive/December2021/01/c2981.html

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting